IP Verse

Pharmaceutical Formulations - EP4233846

The patent EP4233846 was granted to Gilead Sciences on Dec 4, 2024. The application was originally filed on Jun 29, 2016 under application number EP23162978A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP4233846

GILEAD SCIENCES
Application Number
EP23162978A
Filing Date
Jun 29, 2016
Status
Granted And Under Opposition
Nov 1, 2024
Publication Date
Dec 4, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ELKINGTON AND FIFESep 4, 2025ELKINGTON AND FIFEADMISSIBLE
EIPSep 3, 2025EIPADMISSIBLE
HAMM & WITTKOPPSep 2, 2025HAMM & WITTKOPPADMISSIBLE

Patent Citations (14) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO0208241
DESCRIPTIONWO03016306
DESCRIPTIONWO2013025788
OPPOSITIONWO2004064846
OPPOSITIONWO2006135932
OPPOSITIONWO2013025788
OPPOSITIONWO2013116720
OTHERWO0208241
OTHERWO2004064846
OTHERWO2006135932
OTHERWO2013025788
SEARCHWO2013116720
SEARCHWO2015022351
SEARCHWO2015196116

Non-Patent Literature (NPL) Citations (24) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- COSTAGLIOLA D, "Demographics of HIV and aging", Curr. Opin. HIV AIDS, (20140000), vol. 9, no. 4, page 294
DESCRIPTION- JAMBHEKARBREEN, Basic Pharmacokinetics, (20120000), ISBN 978-0853699804
DESCRIPTION- Remington: The Science and Practice of Pharmacy, Lippincott, Williams & Wilkins, (20050000), page 732
DESCRIPTION- ROWLANDTOZER, Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications, (20100000), ISBN 978-0781750097
DESCRIPTION- S.M. BERGE et al., J. Pharma Sci., (19770000), vol. 66, no. 1, pages 1 - 19
OPPOSITION- Anonymous, "Approval Package for aplication number 208351Orig1s000 Odefsey", CENTER FOR DRUG EVALUATION AND RESEARCH, (20160301), pages 1 - 10, CENTER FOR DRUG EVALUATION AND RESEARCH, URL: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208351Orig1s000Approv.pdf, (20201102), XP055745977
OPPOSITION- Anonymous, "Assessment report - Genvoya - Procedure No. EMEA/H/C/004042/0000 ", EMA, (20150924), EMA, URL: https://www.ema.europa.eu/en/documents/assessment-report/genvoya-epar-public-assessment-report_en.pdf, XP093313685
OPPOSITION- Anonymous, "European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Emtricitabine and Tenofovir Alafenamide for HIV Treatment | Business Wire", bussinesswire, (20150528), pages 1 - 2, bussinesswire, URL: https://www.businesswire.com/news/home/20150528005752/en/European-Medicines-Agency-Validates-Gilead’s-Marketing-Application, (20201102), XP055745982
OPPOSITION- Anonymous, "Gilead Discontinues Development of GS 9005 and GS 7340; Company Continues Commitment to Research Efforts in HIV", Gilead, (20041021), Gilead, URL: https://www.gilead.com/news/news-details/2004/gilead-discontinues-development-of-gs-9005-and-gs-7340-company-continues-commitment-to-research-efforts-in-hiv, XP093313674
OPPOSITION- Anonymous, "Truvada 200 mg/245 mg film-coated tablets - Summary of Product Characteristics (SmPC)", EMA, (20200911), XP093313665
OPPOSITION- Brittain Harry G., "Overview of the Solid Dosage Form Preformulation Program", Preformulation in Solid Dosage Form Development, Informa Healthcare, (20080101), pages 347 - 355, XP093313692
OPPOSITION- Charles R Cunningham, et al, "Formulation of acetylsalicylic acid tablets for aqueous enteric film coating", Pharmaceutical Technology, (2001), vol. 25, no. 9, pages 38 - 43, XP055671879
OPPOSITION- Gilead, "Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide for HIV Treatment", Press Release, (20150407), pages 1 - 2, Press Release, (20201207), XP055757389
OPPOSITION- Prasad Telaprolu, M Venkata Anjaneyulu, Y Nagarjuna Reddy, "A REVIEW ON PHARMACEUTICAL EXCIPIENTS", International Journal of Research in Pharmaceutical and Nano Sciences, (20130101), pages 423 - 431, International Journal of Research in Pharmaceutical and Nano Sciences, URL: http://ijrpns.com/article/A%20REVIEW%20ON%20PHARMACEUTICAL%20EXCIPIENTS.pdf, XP055719927
OPPOSITION- "SCIENTIFIC PRINCIPLES OF DOSAGE FORM DESIGN", M.E. Aulton, PHARMACEUTICS: THE SCIENCE OF DOSAGE FORM DESIGN, 2ND EDITION, Churchill Livingstone, (2002), page 128-131
OPPOSITION- Wolfgand A. Ritschel, Ritschel Wolfgang A, Bauer Annette, "Die Tablette", Der Pharmazeutische betrieb, (20020101), pages 64 - 65, XP055371911
OPPOSITION- Ajit S. Narang; Divyakant Desai; Sherif Badawy, "Impact of Excipient Interactions on Solid Dosage Form Stability", Pharmaceutical Research, Kluwer Academic Publishers-Plenum Publishers, NL, NL , (20120616), vol. 29, no. 10, doi:10.1007/s11095-012-0782-9, ISSN 1573-904X, pages 2660 - 2683, XP035111460
OPPOSITION- Albert Mihranyan et al, "Moisture sorption by cellulose powders of varying crystallinity", International Journey of Pharmaceutics, (2004), vol. 269, doi:10.1016/j.ijpharm.2003.09.030, pages 433 - 442, XP055182458
OPPOSITION- DU J, HOAG S W, "THE INFLUENCE OF EXCIPIENTS ON THE STABILITY OF THE MOISTURE SENSITIVE DRUGS ASPIRIN AND NIACINAMIDE: COMPARISON OF TABLETS CONTAINING LACTOSE MONOHYDRATE WITH TABLETS CONTAINING ANHYDROUS LACTOSE", Pharmaceutical Development and Technology, NEW YORK, NY, US, US , (20010101), vol. 06, no. 02, doi:10.1081/PDT-100000742, ISSN 1083-7450, pages 159 - 166, XP009049485
OPPOSITION- Ruane Peter J., Dejesus Edwin, Berger Daniel, Markowitz Martin, Bredeek U. Fritz, Callebaut Christian, Zhong Lijie, Ramanathan Srini, S. Rhee Martin, Fordyce Marshall W., Yale Kitty, "Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1-Positive Adults", JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, LIPPINCOTT WILLIAMS AND WILKINS,PHILADELPHIA, PA, US, US , (20130801), vol. 63, no. 4, doi:10.1097/QAI.0b013e3182965d45, ISSN 1525-4135, pages 449 - 455, XP093107466
OTHER- Kasper Dennis L., "Harrisons Principles of Internal Medicine: Passage", Harrisons Principles of Internal Medicine 19th Edition, (20150901), page 1278, XP093215518
OTHER- Qiu Y., "Developing Solid Oral Dosage forms Pharmaceutical Theory and Practice ", Developing Solid Oral Dosage forms Pharmaceutical Theory and Practice second edition, (20170101), pages 566 - 568, XP093215528
OTHER- YUAN L C, ET AL., "DEGRADATION KINETICS OF OXYCARBONYLOCYMETHYL PRODRUGS OF PHOSPHONATES IN SOLUTION", Environmental Science and Pollution Research, Berlin/Heidelberg, (20010201), vol. 18, no. 02, doi:10.1023/A:1011044804823, ISSN 0724-8741, pages 234 - 237, XP009035540
SEARCH- Gilead, "Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide for HIV Treatment", Press Release, (20150407), pages 1 - 2, URL: https://www.gilead.com/news-and-press/press-room/press-releases/2015/4/gilead-submits-new-drug-application-to-us-food-and-drug-administration-for-fixeddose-combination-of-emtricitabinetenofovir-alafenamide-for-hiv-tre, (20201207), XP055757389 [A] 1-12 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents